How to differentiate major depressive disorder from bipolar depression

Bipolar disorder is common, associated with a loss of 10–20 years of life, and frequently misdiagnosed as major depressive disorder. One-third of patients wait at least 10 years for an accurate diagnosis and an appropriate evidence-based treatment strategy. All patients who present with depressive symptoms should therefore be screened throughout their illness for current and past evidence of hypomania or mania, explained global expert Professor Roger McIntyre, University of Toronto, Canada, at WCP 2021.

Accurate and timely diagnosis is critical to improve outcomes

One-third of patients with bipolar depression wait at least 10 years for accurate diagnosis

Bipolar disorder impairs psychosocial functioning and affects 2–4% of people during their lifetime. It is associated with a loss of approximately 10–20 potential years of life, mainly due to cardiovascular disease and suicide,1 said Professor Roger McIntyre, University of Toronto, Canada.

Accurate and timely diagnosis is therefore critical to enable an appropriate evidence-based treatment strategy, he said.

However, misdiagnosis is common because patients usually present with major depressive disorder (MDD) or with mixed features (see https://progress.im/en/content/how-should-treatment-be-tailored-dsm-5-mi...); and it can be difficult to distinguish bipolar depression from MDD.

Delays in appropriate evidence-based treatment are linked to worse outcomes

Furthermore, MDD converts into bipolar disorder in 3.9% of patients at 1 year, 1% after 2–5 years, and 0.8% after 5–10 years.2

The earlier the age of onset, the more likely a diagnosis of bipolar depression will be missed for many years; and increasing delays in treatment are linked to worse outcomes.3

Approximately one-third of patients wait at least 10 years for accurate diagnosis from the time they first seek treatment.4

All patients who present with depressive symptoms should therefore be screened throughout their illness for current and past evidence of hypomania or mania, said Professor McIntyre.

 

Bipolar depression vs major depressive disorder

A history of poor response to antidepressants may suggest bipolar depression

No symptom is unique to MDD or bipolar depression, said Professor McIntyre, so it is necessary to take a probabilistic approach to build the case. Features that suggest bipolar depression include:

  • Age less than 25 years at onset—up to 75% of patients are less than 25 years of age when they develop symptoms and signs of bipolar disorder1,5
  • Comorbid anxiety disorder, substance use disorder, social phobia and ADHD6,7
  • Psychosis1,5
  • Atypical symptoms and signs—hyperphagia, hypersomnia, and mixed features (the four As—anxiety, agitation, anger/irritability, attentional disturbance-distractibility)1,5
  • A history of poor response to antidepressants8 

 

A tool to differentiate bipolar disorder type I from major depressive disorder

All patients presenting with depressive symptoms should be screened for bipolar disorder

The six-item Rapid Mood Screener (RMS) has been developed by Professor Mcintyre and his colleagues to provide a real-world guidance to primary care practitioners in differentiating bipolar disorder type I from MDD in patients with depressive symptoms9, and comprises six questions to be answered either ‘yes’ or ‘no’.

If at least four of the six items are answered ‘yes’, there is a good probability that the patient has bipolar depression, said Professor McIntyre. Compared with other screening tools, false positives are less likely, and the RMS has good negative predictability.9

 

This Product Theater session was sponsored by Sumitomo Pharma

 

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. McIntyre RS, et al. Lancet 2020;396:1841–56.
  2. Kessing LV, et al. Bipolare Dis. 2017;19: 324–35.
  3. Post RM, et al. J Clin Psychiatry. 2010;71:864–72.
  4. Hirschfeld RM, et al. J Clin Psychiatry. 2003;64:161–74.
  5. McIntyre RS, Calabrese JR. Curr Med Res Opin. 2019;35:1993–2005.
  6. Krishnan KRR. Psychosom Med. 2005;67:1–8.
  7. Wingo AP, Ghaemi SN. J Clin Psych 2007;68:1776–84.
  8. Li C-T, et al. Br J Psychiatry. 2012;200:45–51.
  9. McIntyre RS, et al. Curr Med Res Opin. 2021;37:135–44.

 

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country